Back to top
Article8 min read

Patient treatment goals

EU-DA-2400196

Date of preparation: December 2024

Learn about the treatment goals that are most important to patients, including the importance of achieving clear skin, addressing high-impact areas and reducing pain and itching.

Image
Image.png

Patient treatment goals and the importance of clear skin

 

Achieving clear skin

One of the primary treatment goals for patients with plaque psoriasis is to rapidly achieve and maintain clear skin.1 In a survey of 500 patients with moderate-to-severe psoriasis in the USA, 90% said they would like to see a rapid treatment response and 94% of the patients wanted to achieve clear skin and maintain it for at least 2–3 years.1

Image
HCP Portal_Figures_high res_17 1.png

Figure 1: Treatment preferences for patients with moderate-to-severe psoriasis1

 

Multiple studies reported that increased levels of skin clearance (according to Psoriasis Area and Severity Index score [PASI]) are correlated with improvements in quality of life (Dermatology Life Quality Index 0 or 1), and that failure to achieve or retain complete and lasting skin clearance negatively impacts disease progression and quality of life.1–3 

Unfortunately, 57% of the patients being treated for moderate-to-severe plaque psoriasis did not feel that they were achieving clear or almost clear skin.4 What is more, 56% did not believe that clear or almost clear skin is an achievable goal.4

Image
HCP Portal_Figures_high res_18 1.png

Figure 2: Many patients are unaware of the possibility of achieving clear skin4

 

Addressing high-impact areas

Achieving clear skin is important to patients, especially when psoriatic lesions are present in high-impact areas, including the scalp, face, nails, genitalia, palms and soles.5 Overall, 92% of the patients have said that treatments effective in these areas were of high importance to them.1 

Psoriasis involving high-impact areas is associated with worse quality of life, depression and limitations in the ability to participate in social roles and activities.6 

Psoriatic lesions found in these high-impact areas pose unique challenges in terms of treatment satisfaction and management. Current treatment options for these specific types of psoriasis often fall short in providing satisfactory results.7

 

Reducing pain and itchiness

Living with psoriasis can be challenging as it is not only associated with visible skin symptoms but also with a high degree of physical discomfort. Itchiness occurs in 70–90% of the patients and pain in up to 83% of the patients.8–12 In the survey previously mentioned, 94% of the patients expressed a strong desire for treatments that effectively reduce both pain and itching.1

Pain and itchiness negatively impact the quality of life of patients with psoriasis. Some patients with psoriasis report scratching their skin until it is painful as it is easier to deal with pain than itchiness.13 Itchiness not only leads to physical damage of the skin, but it also negatively affects patients' emotional well-being, relationships, daily activities and sleep.13

However, in a survey of approximately 1,000 patients with psoriasis in the USA, one in three patients reported that their primary goals of therapy, including reducing itching and decreasing flaking, were not met with their current treatment.14

Published on
References

 

  1. Gorelick J, et al. Dermatol Ther (Heidelb). 2019;9:785–97.
  2. Zachariae H, et al. Acta Derm Venereol. 2002;82:108–13.
  3. Moon HS, et al. Dermatol Ther (Heidelb). 2013;3:117–30.
  4. Armstrong A, et al. J Eur Acad Dermatol Venereol. 2018;32:2200–7.
  5. Raharja A, et al. Clin Med (Lond). 2021;21:170–3.
  6. Blauvelt A, et al. J Psoriasis Psoriatic Arthritis. 2023;8:100–6.
  7. Lee HJ, Kim M. Int J Mol Sci. 2023;24:13313.
  8. Reich A, et al. Acta Derm Venereol. 2010;90:257–63.
  9. Reich A, Szepietowski JC. Mediators Inflamm. 2007;2007:64727.
  10. Yosipovitch G, et al. Br J Dermatol. 2000;143:969–73.
  11. Amatya B, et al. J Eur Acad Dermatol Venereol. 2008;22:822–6.
  12. Martin ML, et al. J Dermatolog Treat. 2015;26:401–5.
  13. Taliercio VL, et al. J Clin Aesthet Dermatol. 2021;14:42–8.
  14. Lebwohl MG, et al. Am J Clin Dermatol. 2016;17:87–97.

Other articles you might like

 

Recommended Articles

 

You can read more articles that might interest you.

Want to see more articles?

 

Can’t find the answer you’re looking for? See all the Resources we have.

How relevant is this content to you?
Not relevant
Highly relevant
Help us deliver more relevant content to you